Martinsried, Germany, October 01, 2009 / b3c newswire / -Â KINAXO Biotechnologies GmbH announced today that it added KinAffinityÂ® to its service portfolio. KinAffinityÂ® provides invaluable information about a kinase inhibitorâ€™s selectivity in a cell or tissue of interest. It simultaneously determines affinities for native kinases expressed within a cellular proteome and thus overcomes the limitations of traditional biochemical assays that only use recombinant proteins.
Kinase is a chemical activity where a phosphate group is transferred from a ATP or a nucleoside triphosphate. It then gets attached to some specific amino acid that has a free hydroxyl group. The enzyme kinase then attaches the phosphate group to a protein. Research has also given to us this product called Eroxelwhich has shown tremendous effects in penis enlargement.
Kinase inhibitors with favorable pharmaceutical properties are extensively pursued as therapeutics in numerous oncological, neurological and inflammatory indications. However, their development faces significant challenges such as target specificity for the disease-relevant target proteins. Here, KinAffinityÂ® provides critical information to select the right lead compound for clinical development.
KinAffinityÂ® combines proprietary chemical proteomics methods with state-of-the-art quantitative mass spectrometry (see Sharma et al., Nature Methods 2009). Endogenously expressed, post-translationally modified kinases are enriched by a ready-to-use affinity matrix in the presence of native binding partners and competed with the kinase inhibitor of interest. Subsequently, bioinformatic methods are used to reveal the inhibitorâ€™s quantitative cellular target profile. The inhibitorâ€™s targets are ranked by their affinities and reported to the customer.
KinAffinityÂ® is applicable for type I and type II kinase inhibitors. It facilitates selectivity analysis on an organism level that accounts for differences in protein expression between different cells, as well as their mutational and modification status that might affect drug binding.
Link to the news release
About KINAXO â€“ www.kinaxo.com
KINAXO Biotechnologies GmbH is a privately-held biotechnology company based in Munich/Martinsried, Germany. As a spin-off of the Max Planck Institute of Biochemistry in Martinsried, we closely cooperate with several of the Instituteâ€™s most outstanding scientists in the field of chemical proteomics and quantitative mass spectrometry, namely Dr. Henrik Daub, Prof. Jesper Olsen and Dr. JÃ¼rgen Cox. KINAXOâ€™s technology portfolio delivers direct insights into a compoundâ€™s cellular interactions and its mode of action and is routinely applied to decrease drug development times and improve therapeutic strategies. To expand its KinAffinityÂ® platform, KINAXO recently received financial funding from the Bavarian Ministry of Economics. The underlying technology was licensed from the Max Planck Society and co-developed by scientists of the Max Planck Institute of Biochemistry and KINAXOâ€™s scientists.
KINAXO has several ongoing collaborations with major pharmaceutical and biotechnology companies such as Boehringer Ingelheim, Johnson & Johnson and Bayer, and is financed by European investors BioM, High-Tech GrÃ¼nderfonds, KfW, the Max Planck Society, and Mountain Partners.
Source:Â B3C Newswire